Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
// Maria A. Theodoraki 1 , Celso O. Rezende Jr. 2 , Oraphin Chantarasriwong 2, 3 , Adriana D. Corben 4 , Emmanuel A. Theodorakis 2 and Mary L. Alpaugh 2, 5 1 Department of Biology, Arcadia University, Philadelphia, PA, USA 2 Department of Chemistry and Biochemistry, University of California – San Diego, La Jolla, CA, USA 3 Department of Chemistry, Faculty of Science, King Mongkut’s University of Technology Thonburi, Bangkok, Thailand 4 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 5 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA Correspondence to: Mary L. Alpaugh, e-mail: alpaughm@mskcc.org Emmanuel A. Theodorakis, e-mail: etheodor@ucsd.edu Keywords: drug screening, lymphovascular embolus (LVE), natural products, garcinia xanthone motif (CGX), breast cancer Received: February 16, 2015 Accepted: June 08, 2015 Published: June 18, 2015 ABSTRACT The limited translational value in clinic of analyses performed on 2-D cell cultures has prompted a shift toward the generation of 3-dimensional (3-D) multicellular systems. Here we present a spontaneously-forming in vitro cancer spheroid model, referred to as spheroids MARY-X , that precisely reflects the pathophysiological features commonly found in tumor tissues and the lymphovascular embolus. In addition, we have developed a rapid, inexpensive means to evaluate response following drug treatment where spheroid dissolution indices from brightfield image analyses are used to construct dose-response curves resulting in relevant IC 50 values. Using the spheroids MARY-X model, we demonstrate the unique ability of a new class of molecules, containing the caged Garcinia xanthone (CGX) motif, to induce spheroidal dissolution and apoptosis at IC 50 values of 0.42 +/−0.02 μM for gambogic acid and 0.66 +/−0.02 μM for MAD28. On the other hand, treatment of spheroids MARY-X with various currently approved chemotherapeutics of solid and blood-borne cancer types failed to induce any response as indicated by high dissolution indices and subsequent poor IC 50 values, such as 7.8 +/−3.1 μM for paclitaxel. Our studies highlight the significance of the spheroids MARY-X model in drug screening and underscore the potential of the CGX motif as a promising anticancer pharmacophore.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817
Spheroid-based drug screen: Considerations and practical approach
Friedrich, J., Seidel, C., Ebner, R., & Kunz-Schughart, L. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.226 · Cited by 1,742 · cited 1×
“cellular gel encapsulation) [5, 10–14].”
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array
Tung, Y.-C., Hsiao, A. Y., Allen, S. G., Torisawa, Y.-S., Ho, M., & Takayama, S. (2011) · The Analyst · doi:10.1039/c0an00609b · Cited by 969
Staudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Charoen, K. M., Fallica, B., Colson, Y. L., Zaman, M. H., & Grinstaff, M. W. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.038 · Cited by 187
Ho, W. Y., Yeap, S. K., Ho, C. L., Rahim, R. A., & Alitheen, N. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044640 · Cited by 173 · cited 1×
“Most significantly, rapid measurement of response is essential in any high throughput drug screening model system [25, 61–63].”
BackgroundVörsmann, H., Groeber, F., Walles, H., Busch, S., Beissert, S., Walczak, H., & Kulms, D. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.249 · Cited by 168
Hsiao, A. Y., Tung, Y.-C., Kuo, C.-H., Mosadegh, B., Bedenis, R., Pienta, K. J., & Takayama, S. (2012) · Biomedical Microdevices · doi:10.1007/s10544-011-9608-5 · Cited by 129
Cited by
3D bioprinting for drug discovery and development in pharmaceutics
Peng, W., Datta, P., Ayan, B., Ozbolat, V., Sosnoski, D., & Ozbolat, I. T. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.05.025 · Cited by 313
Current Biomedical Applications of 3D Printing and Additive Manufacturing
Ahangar, P., Cooke, M. E., Weber, M. H., & Rosenzweig, D. H. (2019) · Applied Sciences · doi:10.3390/app9081713 · Cited by 309
Däster, S., Amatruda, N., Calabrese, D., Ivanek, R., Turrini, E., Droeser, R. A., Zajac, P., Fimognari, C., Spagnoli, G. C., Iezzi, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.13857 · Cited by 281
Tumor cells and their crosstalk with endothelial cells in 3D spheroids
Shoval, H., Karsch-Bluman, A., Brill-Karniely, Y., Stern, T., Zamir, G., Hubert, A., & Benny, O. (2017) · Scientific Reports · doi:10.1038/s41598-017-10699-y · Cited by 138
Fibroblast-associated tumour microenvironment induces vascular structure-networked tumouroid
Lee, S. W., Kwak, H. S., Kang, M.-H., Park, Y.-Y., & Jeong, G. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-20886-0 · Cited by 68
Identification of synergistic drug combinations using breast cancer patient-derived xenografts
Turner, T. H., Alzubi, M. A., & Harrell, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-58438-0 · Cited by 50
3D Tumor Spheroid Models for In Vitro Therapeutic Screening of Nanoparticles
Daunys, S., Janonienė, A., Januškevičienė, I., Paškevičiūtė, M., & Petrikaitė, V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_11 · Cited by 32
Metadata
- Authors
- Theodoraki, M. A., Rezende, C. O., Chantarasriwong, O., Corben, A. D., Theodorakis, E. A., & Alpaugh, M. L.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-06-18
- Volume
- 6
- Issue
- 25
- Pages
- 21255-21267
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1882828593
- Cited by
- 57
- References
- 9
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.